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In a follow-up study of children infected with Streptococcus mutans at an early age (children previously shown
to respond poorly to S. mutans GbpB), there was a delay in their immune response, rather than a complete
inability to respond to this antigen. Epitopes in the N-terminal third of GbpB were identified as targets for
naturally induced immunoglobulin A antibody in children at an early age.
Streptococcus mutans is a major dental caries pathogen in
humans. Experimental immunization with S. mutans antigens
involved in the adherence/accumulation of bacteria to tooth
surfaces (AgI/II, glucosyltransferases, and GbpB) has been
shown to induce antibody responses that interfere with S. mu-
tans infection and caries development in animal models (for
reviews, see references 7 and 8). However, the influence of the
immune response in the initial establishment of S. mutans in
children remains poorly understood. We have previously
shown that children infected by S. mutans at an early age
(mean of 17 months) tend to demonstrate a weak salivary
immunoglobulin A (IgA) antibody response to GbpB, while
saliva samples of uninfected children in the same population
(matched for several factors of putative influence on infection
and/or IgA response) often contain high levels of GbpB-reac-
tive IgA antibody (6). Thus, natural salivary IgA antibody re-
sponses to GbpB at an early age may account, in part, for
resistance to S. mutans infection. However, the conditions for
such early IgA responses to GbpB remain unclear. GbpB was
shown to be an immunodominant antigen in adults (9) and
children (10), although the patterns of IgA specificities to S.
mutans antigens vary significantly, even in siblings (10). We
hypothesize that individual patterns of S. mutans antigen
epitopes presented on major histocompatibility complex
(MHC) class II receptors to Th cells might account for some of
these differences. In the present study, we continued to mon-
itor for up to 1 year the patterns of salivary antibody reactivity
with S. mutans antigens in children who had been investigated
in the original study (6) and screened for salivary IgA antibody
to six putative immunodominant GbpB epitopes, selected on
the basis of MHC class II human allele binding.
The study population included 119 of the 160 children en-
rolled in the original study (6) in which the IgA immune re-
sponses had been analyzed, beginning at the ages of 5 to 13
months (baseline; time zero [T0]) and 6 months thereafter (11
to 19 months; T6). In the present study, the levels of S. mutans
infection and patterns of salivary antibody response to S. mu-
tans and Streptococcus mitis (a control oral organism) in these
children were analyzed for a subsequent year at 6-month in-
tervals (T12 and T18). Thus, at the end of the study, children
were between 23 and 31 months of age. Clinical and microbi-
ological exams for diagnosis of caries lesions and levels of S.
mutans infection, respectively, were performed as previously
described (6). Briefly, oral samples collected with sterile
tongue blades were inoculated onto Rodac plates containing
MSB (Difco, Sparks, MD) with 0.2 U bacitracin per ml and
20% sucrose. After incubation (at 37°C in candle jars for 48 h),
the number of S. mutans-like colonies was determined using a
stereoscopic microscope on a predetermined area (1.5 cm2) of
the tongue blade impression. The levels of S. mutans infection
were then expressed as CFU/area. To analyze the influence of
IgA response on early S. mutans infection, a subset of 21 early
S. mutans-infected children were matched to 21 uninfected
children as described elsewhere (6). From these initial 21 pairs,
15 complete pairs remained until the end of the study. Saliva
samples collected at T12 and T18 were clarified and frozen at
70°C as described before (6). Extracted proteins (16 g)
from boiled cells of S. mutans strain 3VF2 and S. mitis strain
ATCC 903 were separated on sodium dodecyl sulfate-6% poly-
acrylamide gels and stained with Coomassie blue R250 (Bio-
Rad, Hercules, CA) to check protein profiles, and the same
batch of the antigen extract was subjected to Western blot
assays for all the study phases (T0 to T18). All these assays
were performed exactly as in the previous study (6). Interassay
variability was controlled using a standard saliva sample ob-
tained from an adult subject that was reassayed in all the study
phases (T0 to T18). Thus, the results of Western blot assays
performed in the two initial study phases (T0 and T6; previ-
ously published in reference 6) could be compared with those
of the subsequent phases (T12 and T18).
The total levels of IgA, IgA1, and IgM were determined in
capture enzyme-linked immunosorbent assays (ELISAs) using
microtiter plates (Costar 3590; Corning, NY) coated for 24 h at
4°C with 2 g/ml goat IgG anti-human IgA or 2 g/ml goat IgG
anti-human IgM in carbonate-bicarbonate buffer, pH 9.6. All
antibody reagents were affinity purified and obtained from
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Zymed Laboratories (South San Francisco, CA). ELISAs were
performed as previously described (6), with the difference that
secondary antibodies for IgA1 and IgM were mouse IgG anti-
human IgA1 (1:500 dilution) and mouse IgG anti-human IgM
(1:500 dilution), respectively. For these isotypes, reactions with
biotin-conjugated goat IgG anti-mouse IgG (1:10,000 dilution)
were followed by overnight incubation with alkaline phos-
phatase-streptavidin (Sigma) (1:500 in phosphate-buffered sa-
line [PBS], pH 7.5). All reactions were revealed by incubation
with p-nitrophenyl phosphate disodium (12), and plates were
read in an ELISA plate reader (VersaMax; Molecular Devices)
to obtain A405 units. The same antibody reagents and standard
dilutions were used for the samples collected in all the study
phases (T0 to T18).
The patterns of reactivity of IgA antibody with S. mutans and
S. mitis antigen extracts were determined in Western blot as-
says using saliva samples collected at T0 and T6 (previously
published [6]) and T12 and T18 for the remaining subset of 15
pairs of infected and uninfected children. Western blots were
performed as detailed in the previous study (6), using the ECL
system (Amersham Biosciences, Little Chalfont, United King-
dom) followed by membrane exposure to X-ray films. Densi-
tometric values of GbpB and other S. mutans antigens reactive
with IgA were obtained by analysis of the digitized X-ray im-
ages using a scanning densitometer (Bio-Rad GS-700 imaging
densitometer). Measures of intensity were expressed as arbi-
trary units (au), and comparisons were made between eight
pairs of infected and noninfected children out of the 15 pairs
analyzed (6). Seven of the 15 pairs were excluded from com-
parisons because the initially infected and/or noninfected child
of the respective pair did not sustain their S. mutans infection
status during the follow-up period (see below).
Sequences that have a high probability of MHC class II
binding may reflect epitopes likely to be involved in the induc-
tion or regulation of immune responses (4). Thus, six GbpB-
derived peptides of predicted MHC class II binding were iden-
tified (11) and assayed against saliva samples (see below) in
order to identify GbpB epitopes responsible for the observed
IgA antibody responses at T0 and T6. Since one or both saliva
samples for three pairs of children were insufficient for assay,
only 18 pairs of children, out of the initial 21 pairs, were
analyzed (T0 to T6) for antiepitope activity. Saliva samples
were diluted 1:20 in PBS-BN (PBS containing 1% bovine se-
rum albumin [Sigma] and 0.05% sodium azide [pH 7.4]) with
2.0% Prionex stock (PentaPharm Ltd., Basel, Switzerland),
decomplemented at 56oC for 30 min, followed by adsorption
onto and then elution (by centrifugation) from Wekcell cellu-
lose sponges to reduce mucin content. Salivary IgA reactivities
with GbpB peptides were tested using a particle-based multi-
plex fluorescence immunoassay (Luminex Corp., Austin, TX).
Fluorescently tagged microspheres were coated with GbpB
purified by fast-performance liquid chromatography or with




ANY (390-YVTGVQGGQIQVQEANYAG-409), or SIG
(412-SIGNYRGWFNPGSVSYIYPN-431). Mixtures for assay
contained (i) a combination of all peptide-coated microspheres
or (ii) GbpB-coated microspheres. Then 50-l portions of the
bead mixtures were added to the wells on 1.2-m-pore-size
filter plates (Millipore Corp., Bedford, MA). Microspheres
were then washed twice with PBS-BN under vacuum and re-
suspended in 50 l of the same buffer. Fifty microliters of each
diluted saliva sample (1:8 in PBS-BN) was then added and
incubated at 37°C with shaking for 120 min. After the buffer
was drained under vacuum, microspheres were incubated with
a 1:500 solution of goat anti-human IgA (Jackson Immunore-
search) in PBS-BN for 30 min at 37°C. Microspheres were then
incubated with a 1:250 solution of R-phycoerythrin-conjugated
donkey anti-goat IgG (Jackson Immunoresearch) for 30 min at
37°C. All incubations were performed in the dark. After the
samples were washed, they were resuspended in PBS-BN and
read in a Luminex 100 analyzer. Results were reported as
median fluorescence intensity (FI).
Figure 1 shows changes in the mean levels of salivary IgA,
subclass IgA1, and IgM in the 119 studied children. The IgA1
subclass accounted for the majority of the salivary IgA in all
phases (518.76  198.0 g/ml, mean  standard deviation at
T18), but the proportion of IgA1 in relation to total IgA de-
creased at T18. The levels of IgM were minimal throughout the
study.
The S. mutans infection status changed in several infected
and noninfected children during the course of the study.
Among the 15 children in whom S. mutans infection was ini-
tially detected (infected group), S. mutans could not be de-
tected in five of these subjects at either T12 or T18. The mean
S. mutans infection level of these five children at T6 was 26.5
CFU/area (41.5), and the range of salivary IgA antibody
reaction with GbpB in Western blot assays varied from unde-
tectable to 342.0 au at T6 (median, 35.6 au). In addition, at T6,
4 of the 15 children in whom S. mutans was initially undetect-
able became detectably infected (59.3  36.3 CFU/area [T12]
and 30.5  46.5 CFU/area [T18]). Reactivity with GbpB in
these children ranged from undetectable to 399.7 au (median,
53.8) at T6. To simplify the analysis, pairs that included chil-
dren whose S. mutans infection status changed from T0 to T6
were excluded, i.e., comparisons of the IgA reactivities were
performed on the eight pairs of infected and noninfected chil-
dren who sustained their status of infection during the com-
plete study period (T0 to T18).
Carious lesions were detected at T12 and T18 in three
FIG. 1. Levels of salivary IgM and IgA1 and total IgA observed
during a 1.5-year longitudinal study of 119 children. Immunoglobulins
were measured by ELISAs at T0 (baseline) and T6, T12, and T18 for
6-, 12-, and 18-month follow-up analysis.
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(37.5%) and four (50.0%) children, respectively, in the initially
infected group. The four children affected at T18 included the
same three with caries lesions at T12. The mean numbers of
caries lesions were 0.6 (1.1) and 1.4 (1.9), respectively, at
these time intervals. None of the noninfected children showed
lesions during the end of the study. Both groups showed similar
increases in total salivary IgA protein at T6 to T18 (infected
group, 455.8  173.5 and 932.0  298.5 g/ml, respectively;
noninfected group, 469.9  144.8 and 866.3  294.7 g/ml,
respectively).
Shown in Fig. 2 are the salivary IgA antibody levels to S.
mutans GbpB throughout the study period. The median inten-
sities of salivary IgA antibody levels reactive with GbpB were
significantly higher at T6 in the noninfected group compared
with the infected group (Mann-Whitney, P  0.05). No signif-
icant differences were observed, however, between the overall
levels of IgA antibody reactivity with S. mutans and S. mitis
antigen extracts in either group (data not shown). Interestingly,
at T18, the mean level of GbpB-reactive IgA antibody had
declined from the peak response in the noninfected group. The
IgA antibody response to GbpB was delayed in the infected
group. By T12, the saliva samples of many infected children
contained detectable antibody to GbpB, although as a group
this increase in intensity was not statistically significant. The
levels of S. mutans infection in the infected group also tended
to increase from T0 to T12, although no significant variability
was seen in the level of infection in this time frame. At the later
collection points, the distributions of anti-GbpB antibody in-
tensities were similar in the infected and noninfected groups.
Thus, the data seem to suggest that the infected group’s im-
mune response to S. mutans GbpB was delayed compared with
that observed in the noninfected group. Reasons for this ap-
parent delay remain to be explained, but we speculate that the
GbpB-specific IgA responses that developed in the infected
children at T12 were due to the increased S. mutans antigenic
challenge, as reflected by the increasing S. mutans levels of
infection at the same period (Fig. 2). Interestingly, after the
increased IgA response to GbpB in the infected group, S.
mutans infection levels tended to decrease or at least to stabi-
lize (from T12 to T18) (Fig. 2). Thus, vaccination approaches
to direct patterns of IgA response to S. mutans protective
epitopes before or at the very initial challenge for S. mutans
infection might be very helpful to prevent infection at an early
age. On the other hand, GbpB homologues have been found in
other pathogens and commensal organisms of the mucosa, e.g.,
Streptococcus pneumoniae, Streptococcus agalactiae, Enterococ-
cus faecium, and Streptococcus sanguinis (5, 13). Thus, it will be
important to analyze how levels of IgA reactive with GbpB
homologues are associated with the initial colonization by
these organisms and to identify cross-reactive epitopes.
To gain insight into the GbpB epitope-specific nature of the
initial mucosal immune responses to this protein, salivary IgA
antibody reactive with six 20-mer GbpB peptides was measured
by the Luminex fluorescence assay. Figure 3 summarizes the
salivary IgA antibody reactivity to these peptides observed in
saliva samples from infected and noninfected children taken at
T0. Significant levels of salivary IgA antibody activity were
observed for three peptides in the N-terminal third (VAR,
QGQ, and SYI) and one peptide (SIG) at the C terminus of
GbpB. Salivary antibody levels to the VAR and QGQ peptides
were significantly correlated (Spearman rank) at T0 with anti-
body levels to GbpB (r2  0.404 and P  0.015 and r2  0.357
and P  0.026, respectively), strengthening their relationship
to GbpB-induced responses. No obvious differences were ob-
served, however, between salivary IgA antipeptide levels in
infected versus noninfected children at T0 (Fig. 3) or T6 (Fig.
4). Although not reaching statistical significance, the median
salivary IgA antibody levels to intact GbpB (measured in the
multiplex assay) in noninfected children were higher (102 FI
and 128 FI, respectively) at T0 and T6 than those of infected
children (48 FI and 94 FI, respectively), paralleling the GbpB-
reactive antibody levels observed on Western blots.
FIG. 2. Comparisons of the mean intensities of Western blot reac-
tivity of salivary IgA antibody with native GbpB between the subset of
eight infected children (shaded bars) and their noninfected counter-
parts (black bars). The mean levels of S. mutans infection observed in
the infected group are indicated (Œ; see the right-hand y axis). The
solid and dashed error bars show the standard deviations for the IgA
intensities of the reaction and levels of S. mutans infection, respec-
tively. Significant differences in median values between the infected
and uninfected groups are indicated by the asterisk (Mann-Whitney U
test, P  0.028).
FIG. 3. Box plots of FI of salivary IgA antibody reactivity with
microspheres coated with 20-mer GbpB-derived peptides. Saliva sam-
ples were obtained from S. mutans-infected (n  18) and nondetect-
ably infected (n  18) children at T0. Median values are indicated by
the horizontal lines within the boxes. The boxes span the 25th and 75th
percentiles, while the error bars subsume the 90th and 10th percentiles
and solid black circles indicate the 5th and 95th percentiles.
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The oral cavity has a highly diverse indigenous microbiota
that increases in complexity as teeth erupt in the mouth (1, 3,
10). The effect of the salivary IgA response on the establish-
ment of commensal and pathogenic species could provide im-
portant insights to understanding susceptibility to infection and
directing suitable immunization strategies to control pathogen
infection. Previously, we have shown that the presence and
intensity of salivary IgA antibody reactivity to GbpB measured
on Western blots during the first 12 to 18 months of life are
negatively associated with S. mutans infection (6). In this study
we show that GbpB-specific salivary antibody responses, again
measured on Western blots, continue to increase, but are self-
limiting in both S. mutans-infected children and children with
nondetectable infection. Interestingly, the decrease in salivary
IgA antibody to GbpB seen in noninfected children at T18
occurred during a phase of apparent maturation of the IgA
response, as indicated by a reduction in the proportion of IgA1
subclass in relation to total IgA at this time (Fig. 1) which is
more typical of older children and adults (2, 12).
To investigate whether differences in the intensities of re-
sponse to GbpB between infected and noninfected children
would be associated with distinct patterns of GbpB epitope
recognition, we selected saliva samples collected at the study
phases T0 and T6 (Fig. 2) where differences in salivary IgA
antibody reactive with the native GbpB protein were more
striking. Although Luminex measurements of saliva samples
suggested that noninfected children had somewhat higher lev-
els of IgA antibody to GbpB N-terminal peptides than infected
children, these differences at T0 and T6 were not as remark-
able as those observed in the Western blot assays for GbpB
(Fig. 2). It is possible that GbpB reactivity detected in the
Luminex assays reflects only external hydrophilic parts of the
protein or antigenic determinants dependent on the GbpB
native conformation. Since Western blots use denatured
GbpB, this assay might reflect a higher/different array of reac-
tive GbpB epitopes than are exposed when protein is attached
to microspheres.
Analysis of salivary IgA antibody reactivity revealed that the
region between GbpB residues 52 and 132 (peptides QGQ,
VAR, and SYI) contained several linear epitopes to which
children apparently responded following initial S. mutans chal-
lenges. Furthermore, two of these “responses” were signifi-
cantly correlated with salivary IgA antibody levels to GbpB.
These data indicate that subunit vaccines based on GbpB se-
quence should contain some or all of this sequence. Also,
tracking antibody responses to epitopes in this region may
correlate with early exposure to S. mutans, since these antibody
specificities were observed in saliva samples of children in
whom S. mutans had not yet been detectably incorporated into
the oral biofilm.
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percentiles.
VOL. 14, 2007 NOTES 807
 on A
ugust 23, 2013 by C
O
N
S
O
L.C
A
P
E
S
-T
299093
http://cvi.asm
.org/
D
ow
nloaded from
 
